NCT04884243已完成2 期
A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- IOP of Study Eye Related to Safety
研究概览
简要总结
STUDY DESIGN
Structure:
Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.
Duration:
3 months of TID treatment.
Treatment Groups, Dosing, and Treatment Regimen:
Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle
详细描述
Structure:
Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.
Duration:
3 months of TID treatment.
Treatment Groups, Dosing, and Treatment Regimen:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with MGD in both eyes and meet the following:
- •Ocular discomfort Score (ODS) ≥ 2
- •Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories
- •Total Cornea staining grade ≥ 3
- •Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid
- •Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye
- •BCVA LogMAR ≥ +0.7 in each eye
- •All patients of both genders ≥ 18 years
- •Willing to withhold the use of artificial tears and lubricants during the treatment phase;
- •Able to provide written informed consent and comply with study assessments for the full duration of the study.
排除标准
- •Uncontrolled systemic disease in the opinion of the Investigator
- •Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness
- •History of ocular herpes disease in either eye
- •Incisional ocular surgery within 6 months or ocular laser surgery within 3 months
- •Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening
- •Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.)
- •Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.)
- •Active rosacea involving the eyelids within 60 days of screening
- •Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study
- •Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
- •Female patients who are pregnant, nursing, or planning a pregnancy during the study
研究组 & 干预措施
CBT-006
Placebo Comparator
Vehicle
干预措施: CBT-006 (Drug)
CBT-006 lower concentration
Experimental
lower concentration dose
干预措施: CBT-006 (Drug)
CBT-006 higher concentration
Experimental
higher concentration dose
干预措施: CBT-006 (Drug)
结局指标
主要结局
IOP of Study Eye Related to Safety
时间窗: 12 weeks
Intraocular Pressure of study eye related to safety
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland DysfunctionMeibomian Gland DysfunctionNCT05261386Cloudbreak Therapeutics, LLC95
已完成
2 期
A Clinical Trial to Assess Subjects With Dry Eye Disease.Dry EyeNCT04971031Aldeyra Therapeutics, Inc.158
已完成
2 期
Safety and Efficacy Study of CBT-004 in Patients With Vascularized PingueculaPingueculaNCT04884256Cloudbreak Therapeutics, LLC88
已完成
2 期
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract SurgeryInflammationNCT06164743VivaVision Biotech, Inc91
已完成
2 期
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye SyndromeNCT03404115Aldeyra Therapeutics, Inc.300